CClinicalTrials.gg
RecruitingNCT07063732Updated Jul 14, 2025

Ketone Monoester Supplements, High Altitude, and Brain Blood Flow During Exercise

An interventional study of Ketone Monoester (KME) and Placebo in High Altitude Hypoxia and Exercise, sponsored by McMaster University. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by McMaster University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this trial is to investigate the effect of acute ketone monoester ingestion (0.6 g KME/kg body weight) on the occurrence of the ventilatory threshold and the subsequent response of blood velocity in cerebral arteries during a maximal exercise test at low altitude and high altitude.

02

Conditions studied

  • High Altitude Hypoxia
  • Exercise

Browse trials for

03

In context

Motor Activity

2,431 studies on the registry are indexed under Motor Activity; 1,162 are open to participants now.

This study's planned enrollment of 14 is below the median of 60 across 2,123 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

McMaster University is the lead sponsor of 720 studies on the registry; 123 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

- Must be a member of the research expedition team travelling to the Barcroft Research Station in White Mountain California

Exclusion criteria

Exclusion Criteria:

  • BMI > 30
  • No prescribed medications (oral contraceptives excluded)
  • History of smoking
  • Currently following a ketogenic diet or consuming exogenous ketogenic supplements
  • History of heart, lung, blood vessel, or kidney disease
  • Currently pregnant
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    High Altitude (3800m; Barcroft Research Station)

    High altitude setting

    Dietary Supplement: Ketone Monoester (KME) · Dietary Supplement: Placebo

  • Experimental
    Low Altitude (334m; University of Guelph)

    Low altitude setting

    Dietary Supplement: Ketone Monoester (KME) · Dietary Supplement: Placebo

Interventions

  • Dietary supplementKetone Monoester (KME)

    0.6 g KME per kg body mass; \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate. (Delta G Ketone, TΔS, Oxford).

  • Dietary supplementPlacebo

    Inert, calorie-free placebo drink that is taste-matched to the ketone monoester supplement

06

What researchers measure

Primary outcomes

  1. Cerebral Blood Velocity

    Transcranial Doppler ultrasound will be used to measure blood velocity in the middle cerebral artery and posterior cerebral artery. Location of measurements will remain consistent within participants.

    Time frame: 3 hours

Secondary outcomes

  1. Cardiac Output

    Cardiac output (L/min) will be measured using a non-invasive cardiac output monitor (Physioflow). The monitor uses signal morphology impedance cardiography to determine cardiac output.

    Time frame: 3 hours

  2. Blood Pressure

    Mean arterial pressure (mmHg) will be measured via a brachial cuff placed on the upper arm.

    Time frame: 3 hours

  3. Ventilatory Threshold

    Ventilatory threshold (VT) will be calculated based on previously described methods (Gaskill et al., 2001).

    Time frame: 3 hours

  4. End-Tidal Gases

    End-tidal oxygen (PETO2) (mmHg) and carbon dioxide (PETCO2) (mmHg) will be collected using a metabolic cart.

    Time frame: 3 hours

  5. Rate of Oxygen Consumption and Carbon Dioxide Production

    Rate of oxygen consumption (VO2) (mL/min) and carbon dioxide production (VCO2) (mL/min) will be collected using a metabolic cart.

    Time frame: 3 hours

  6. Ventilation

    Ventilation (Ve) (L/min) will be collected using a metabolic cart.

    Time frame: 3 hours

  7. Blood Lactate and Beta-Hydroxybutyrate

    Capillary blood will be obtained via finger prick using a lancing device to measure concentrations of blood lactate (mmol/L) and beta-hydroxybutyrate (mmol/L) using a handheld metabolite analyzer.

    Time frame: 3 hours

  8. Peak Work Rate (Maximal Exercise Test)

    The maximum wattage (W) achieved by the participant during the maximal exercise test will be recorded.

    Time frame: 3 hours

07

Study locations

2 of 2 sites recruiting
  • Barcroft Research Station
    Bishop, California 93514, United States
    Recruiting
  • University of Guelph
    Guelph, Ontario N1G 2W1, Canada
    Recruiting
08

References and documents

Publications

  • Gaskill SE, Ruby BC, Walker AJ, Sanchez OA, Serfass RC, Leon AS. Validity and reliability of combining three methods to determine ventilatory threshold. Med Sci Sports Exerc. 2001 Nov;33(11):1841-8. doi: 10.1097/00005768-200111000-00007. PubMed 11689733 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063732
Lead sponsor
McMaster University
Responsible party
Jeremy Walsh (Assistant Professor, McMaster University) — Principal investigator
First posted
Jul 14, 2025
Start date
May 28, 2025
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Jul 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion